GTN

GTN was a London-based biotechnology company that developed a unique platform for AI-driven drug discovery by combining quantum physics with machine learning. The company's core technology, Generative Tensorial Networks, allowed for the simulation of molecular structures and the prediction of their properties with high accuracy, aiming to discover novel small molecule therapeutics. By integrating quantum mechanical descriptors into deep learning frameworks, GTN sought to overcome the limitations of traditional drug discovery methods. The company was acquired by Exscientia in March 2022 to bolster its AI-driven drug design and discovery capabilities.